Keating, C., Yonker, L. M., Vermeulen, F., Prais, D., Linnemann, R. W., Trimble, A., Kotsimbos, T., Mermis, J., Braun, A. T., O’Carroll, M., Sutharsan, S., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Floreth, T., Michelson, P., Sosnay, P. R., … Horsley, A. (2025). Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00411-9

Kay, D. M., Sadeghi, H., Kier, C., Berdella, M., DeCelie‐Germana, J. K., Soultan, Z. N., Goetz, D. M., Caggana, M., Fortner, C. N., Giusti, R., Kaslovsky, R., Stevens, C., Voter, K., Welter, J. J., & Langfelder‐Schwind, E. (2024). Genetic counseling access and service delivery in New York State is variable for parents of infants with complex CFTR genotypes conferring uncertain phenotypes. Pediatric Pulmonology, 59(7), 1952–1961. Portico. https://doi.org/10.1002/ppul.27023

Rose, N. R., Chalamalla, A. R., Garcia, B. A., Krick, S., Bergeron, J., Sadeghi, H., Schellhase, D. E., Ryan, K. J., Dowell, A. E., Acosta, E. P., & Guimbellot, J. S. (2024). Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulmonary Pharmacology & Therapeutics, 86, 102301. https://doi.org/10.1016/j.pupt.2024.102301